Diabetes & Obesity Drug Development Pipeline Review, 2016

US$ 3995

The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications. While products indicated for obesity do not currently have a large market presence, there are a large number of these products in the pipeline, with the majority in early stages of development.

11-22 2016   Pages: 560

Ophthalmology Drug Development Pipeline Review, 2016

US$ 3995

Ophthalmology disorders are associated with the eyes and visual system. If left untreated, serious long-term co-morbidities such as diabetes, and particularly blindness, can arise.

11-22 2016   Pages: 633

Global Cardiovascular Disease Market to 2022 – Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

US$ 4995

“Global Cardiovascular Disease Market to 2022 – Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

11-14 2016   Pages: 192

Frontier Pharma: Ophthalmology Therapeutics – Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

US$ 6995

“Frontier Pharma: Ophthalmology Therapeutics – Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

11-14 2016   Pages: 70

Global Gastrointestinal Drug Market to 2022 – Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape

US$ 4995

“Global Gastrointestinal Drug Market to 2022 – Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape

11-09 2016   Pages: 161

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 – Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

US$ 4995

“Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 – Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

11-09 2016   Pages: 112

Frontier Pharma: Glioblastoma Multiforme – Cancer Immunotherapies Dominate First-in-Class Product Innovation

US$ 6995

“Frontier Pharma: Glioblastoma Multiforme – Cancer Immunotherapies Dominate First-in-Class Product Innovation

11-09 2016   Pages: 73

Frontier Pharma: Glioblastoma Multiforme – Cancer Immunotherapies Dominate First-in-Class Product Innovation

US$ 6995

Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is the most common and aggressive human brain tumor, accounting for 15.4% of all primary brain tumors and 60-75% of all astrocytomas.

10-17 2016   Pages: 73

Alzheimer’s Therapeutics in Asia-Pacific Markets to 2021 – Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies

US$ 4995

Alzheimer’s Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. Symptoms typically begin to first occur in patients in their mid-sixties, appearing in varying stages.

04-15 2016   Pages: 151

Asthma Therapeutics in Asia-Pacific Markets to 2021 – High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns

US$ 4995

Asthma treatment can be classed as either a long-term control medication, aimed at controlling persistent asthma, or a quick-relief medication, for the relief of exacerbations and acute symptoms. Long-term control medication includes Inhaled Corticosteroids (ICS), immunomodulators, leukotriene modifiers, cromolyn sodium, nedocromil and methylxanthines.

04-15 2016   Pages: 130
Contact With Us
Join templatemonster at google+
Customized Research
Request Sample